Rothwell Investment Advisors, LLC’s Neurocrine Biosciences NBIX Stock Holding History

Rothwell Investment Advisors, LLC’s Portfolio NBIX Stock Details NBIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$18.4K	Buy	+130	New	+$20.9K	0.01%	645

Other funds holding NBIX

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Thrivent Financial for Lutherans Minneapolis, Minnesota $61B AUM 26.92% 1-Year Est. Return

Aberdeen Group Edinburgh, United Kingdom $72.4B AUM 24.61% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return

Swedbank Stockholm, Sweden $118B AUM 40.52% 1-Year Est. Return

Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return

Ninety One (UK) London, United Kingdom $45.5B AUM 15.2% 1-Year Est. Return

KBC Group Brussels, Belgium $47.9B AUM 37.61% 1-Year Est. Return

Barclays London, United Kingdom $500B AUM 36.84% 1-Year Est. Return

Pictet Asset Management Carouge, Switzerland $106B AUM 32.76% 1-Year Est. Return

Rothwell Investment Advisors, LLC's NBIX Position: Q3 2026 in Review

Rothwell Investment Advisors, LLC opened a new position in Neurocrine Biosciences (NBIX) in Q3 2026: 130 shares worth $18.4K. The stake represents 0.01% of the portfolio and ranks #645 among its holdings.

362 funds tracked by Wall St. Rank hold NBIX as of Q3 2026.

Rothwell Investment Advisors, LLC held 130 shares of Neurocrine Biosciences worth $18.4K as of Q3 2026.
Neurocrine Biosciences was a new Rothwell Investment Advisors, LLC position in Q3 2026.
Neurocrine Biosciences made up 0.01% of Rothwell Investment Advisors, LLC's portfolio in Q3 2026, its #645 holding.
362 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q3 2026.

Based on Rothwell Investment Advisors, LLC's 13F filing for Q3 2026, filed 6 Nov 2026.